NCT04498910View on ClinicalTrials.gov

A Study of LY3451838 in Participants With Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

November 9, 2022

Study Completion Date

November 9, 2022

Conditions
Migraine
Interventions
DRUG

LY3451838

Administered IV

DRUG

Placebo

Administered IV

Trial Locations (9)

23606

Health Research of Hampton Roads Inc, Newport News

32504

Emerald Coast Center for Neurological Disorders, Pensacola

34470

Renstar Medical Research, Ocala

63303

StudyMetrix Research, City of Saint Peters

65810

Clinvest Research LLC, Springfield

85004-0000

21st Century Neurology, a division of Xenoscience, Phoenix

06905

New England Institute for Clinical Research, Stamford

33612-4799

University of South Florida, Tampa

08755

Bio Behavioral Health, Toms River

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04498910 - A Study of LY3451838 in Participants With Migraine | Biotech Hunter | Biotech Hunter